Clinical value of serum tumor marker CA19_9 in pancreatic carcinoma
ClinicalvalueofserumtumormarkerCA19_9inpancreaticcarcinoma,Correspondenceto,Abstract,AIM,METHODS,RESULTS,CONCLUSION,Subjectheadings,INTRODUCTION,PATIENTSANDMETHODS,Patients,SerumCA19_9assay,Statisticalanalyses,RESULTS,SerumCA19_9invariousdigestivetractdis
Department of Hepatobiliary Surgery, Affiliated Ganquan Hospital, Shanghai Tiedao University, Shanghai 200025, ChinaYue_Zu Fan, Associate professor of surgery, Vice Director, Member of the International Gastro_Surgical Club and Chinese Surgical Association, Associate Editor_in_chief of China Medical Abstracts: Surgery (in English), havi ng 74 papers and 5 books published.
Tel. +86·21·56051080-1107
Presented at the 6th Chinese Conference of Pancreatic Surgery, Guiyang, 4～9 October, 1996.
Correspondence to Dr. Yue Zu Fan
Received 1996-10-26
Abstract
AIM To evaluate the clinical value of serum CA19_9 as a marker for pancreatic carcinoma.
METHODS Serum CA19_9 levels determined serially by immunoradi ometric assay in 40 patients with pancreatic carcinoma, 92 with other gastrointestinal carcinomas and 115 with benign pancreaticobiliary diseases. In the patients with pancreatic carcinoma preoperative examinations include iste d routine ultrasonography, CT_scan of the abdomen, PTC and/or ERCP; clinical courses with respect to the pathological data, surgical procedures employed and the prognosis of these patients were followed up and compared. ......
您现在查看是摘要页，全文长 23803 字符。